<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363776</url>
  </required_header>
  <id_info>
    <org_study_id>CA034-001</org_study_id>
    <secondary_id>2017-002199-24</secondary_id>
    <nct_id>NCT03363776</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers</brief_title>
  <official_title>Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986277 given alone
      and in combination with Nivolumab in patients with epithelial cancers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 24, 2017</start_date>
  <completion_date type="Anticipated">December 29, 2022</completion_date>
  <primary_completion_date type="Actual">November 22, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AE)</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events (SAE)</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AEs meeting dose limiting toxities criteria</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AEs leading to discontinuation</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AEs resulting in death</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory test abnormalities</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of vital sign abnormalities</measure>
    <time_frame>Up to 842 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (mDOR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival (mPFS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed blood concentration (Cmax)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed blood concentration (Tmax)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood concentration-time curve from time zero to time of last quanitifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (T-HALF)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (Vss)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of the elimination phase (Vz)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration over a dosing interval (AUC[0-48]/48) (Css-avg)</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 administered alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 administered in combination with Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986277 monotherapy with option for subsequent Nivolumab therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986277</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Dose Escalation Therapy</arm_group_label>
    <arm_group_label>Combination Expansion Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-963558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histological or cytological confirmation of metastatic and/or unresectable metastatic
             colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with
             measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per
             PCWG3

          -  Presence of at least 2 lesions: at least one with measurable disease as defined by
             RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response
             assessment; at least 1 lesion must be accessible for biopsy in addition to the target
             lesion

          -  Participants must have received, and then progressed or been intolerant to, at least 1
             standard treatment regimen in the advanced or metastatic setting, if such a therapy
             exists, and have been considered for all other potentially efficacious therapies prior
             to enrollment

          -  ECOG performance status less than or equal to 2

        Exclusion Criteria:

          -  Participants with active central nervous system (CNS) metastases, untreated CNS
             metastases, or with the CNS as the only site of disease

          -  Participants with carcinomatous meningitis

          -  Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
             anti-cancer therapy and initiation of study treatment

          -  Participants with active, known, or suspected autoimmune disease

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

